143 related articles for article (PubMed ID: 11028247)
1. 20th-century advances in drug therapy in oncology--Part. II.
Dutcher JP; Novik Y; O'Boyle K; Marcoullis G; Secco C; Wiernik PH
J Clin Pharmacol; 2000 Oct; 40(10):1079-92. PubMed ID: 11028247
[TBL] [Abstract][Full Text] [Related]
2. New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group.
Niitani H; Fukuoka M; Furuse K; Kudoh S; Kurita Y; Ohnoshi T; Saijoh N
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():117-9. PubMed ID: 9210893
[No Abstract] [Full Text] [Related]
3. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Sinha BK
Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy.
Zelnak AB
Methods Mol Med; 2007; 137():209-34. PubMed ID: 18085232
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase I inhibitors.
Takimoto CH; Kieffer LV; Arbuck SG
Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
[No Abstract] [Full Text] [Related]
7. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
8. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
Martino E; Casamassima G; Castiglione S; Cellupica E; Pantalone S; Papagni F; Rui M; Siciliano AM; Collina S
Bioorg Med Chem Lett; 2018 Sep; 28(17):2816-2826. PubMed ID: 30122223
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of topoisomerase-interactive drugs.
Muggia FM; Burris HA
Adv Pharmacol; 1994; 29B():1-31. PubMed ID: 8996599
[No Abstract] [Full Text] [Related]
10. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.
Parissenti AM; Hembruff SL; Villeneuve DJ; Veitch Z; Guo B; Eng J
Anticancer Drugs; 2007 Jun; 18(5):499-523. PubMed ID: 17414620
[TBL] [Abstract][Full Text] [Related]
12. Recent patents therapeutic agents for cancer.
Li X; Xu W
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):255-84. PubMed ID: 18221041
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerases in cancer therapy.
Lock RB; Ross WE
Anticancer Drug Des; 1987 Oct; 2(2):151-64. PubMed ID: 2835059
[TBL] [Abstract][Full Text] [Related]
14. Vinca alkaloids vs. taxanes as therapy in lymphoid malignancies: do our experimental models obscure our understanding of how these drugs really work?
Lerner A; Andrea N
Cancer Invest; 2005; 23(1):100-2. PubMed ID: 15779874
[No Abstract] [Full Text] [Related]
15. Antimitotic drugs in the treatment of cancer.
van Vuuren RJ; Visagie MH; Theron AE; Joubert AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1101-12. PubMed ID: 26563258
[TBL] [Abstract][Full Text] [Related]
16. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Pourquier P; Pommier Y
Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I inhibitors: camptothecins and beyond.
Pommier Y
Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 1.
Walker K; Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):513-6. PubMed ID: 17665320
[No Abstract] [Full Text] [Related]
19. [Extra- and paravasation of cytotoxic drugs. Pathomechanisms and current preventive measures].
Lipp HP
Med Monatsschr Pharm; 2010 Mar; 33(3):87-94; quiz 95-6. PubMed ID: 20355670
[TBL] [Abstract][Full Text] [Related]
20. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Zamora JM; Pearce HL; Beck WT
Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
